(Total Views: 534)
Posted On: 06/02/2025 11:09:30 AM
Post# of 155727
your student on Stocktwits brings another link:
https://talkmarkets.com/content/stocks--equit...rid=166882
"In short, the critical takeaway from CytoDyn’s ESMO showing is that the company delivered, for the first time, a coherent mechanistic explanation (PD-L1 induction via CCR5 blockade) that dovetails with its extraordinary long-term survival anecdotes. This elevates leronlimab from an interesting case series to a candidate with a testable, potentially platform-wide value proposition in solid-tumor oncology. This Biotech Company is also preparing to launch and join some of the other companies currently selling their shares between ranges $3.25 - $17.85 a share. The explosive potential for Cytodyne to one day be seen as a Penny Stock and in the same day be trading in the multiple dollars per share. "
Seems, the author has a lot of shares?
https://talkmarkets.com/content/stocks--equit...rid=166882
"In short, the critical takeaway from CytoDyn’s ESMO showing is that the company delivered, for the first time, a coherent mechanistic explanation (PD-L1 induction via CCR5 blockade) that dovetails with its extraordinary long-term survival anecdotes. This elevates leronlimab from an interesting case series to a candidate with a testable, potentially platform-wide value proposition in solid-tumor oncology. This Biotech Company is also preparing to launch and join some of the other companies currently selling their shares between ranges $3.25 - $17.85 a share. The explosive potential for Cytodyne to one day be seen as a Penny Stock and in the same day be trading in the multiple dollars per share. "
Seems, the author has a lot of shares?
(7)
(0)
